Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2

Area of Science:

• Biochemistry
• Molecular Biology
• Genetics

Background:

• Cystic fibrosis (CF) is a lethal autosomal recessive disease caused by CFTR gene mutations.
• The F508del mutation leads to CFTR protein misfolding and reduced surface expression.
• CFTR modulators, including potentiators and correctors, aim to restore CFTR function.

Purpose of the Study:

• To elucidate the mechanism of action and binding site of elexacaftor (VX445), a CFTR corrector.
• To identify protein domains affected by VX445 in the context of F508del CFTR.
• To understand how VX445 contributes to the efficacy of triple-combination CFTR therapies.

Main Methods:

• Biochemical analyses of F508del CFTR in HEK 293 cells.
• Investigation of VX445 activity on specific CFTR protein domains.
• Assessment of VX445's additive effects with other CFTR correctors.

Main Results:

• VX445 specifically enhances the expression and maturation of the MSD2 domain of CFTR.
• The effect of VX445 on functional F508del CFTR expression is additive with existing CFTR correctors.
• VX445's mechanism involves improving the processing of specific CFTR domains.

Conclusions:

• VX445 plays a crucial role in improving F508del CFTR maturation and function.
• This study provides insights into CFTR protein processing defects and potential therapeutic strategies.
• Findings support the development of novel CFTR correctors targeting mutation-specific defects.